吉瑞替尼在既往接受过FLT3抑制剂治疗的复发/难治性FLT3突变急性髓系白血病中的临床活性
该回顾性分析纳入11家美国中心的113例复发/难治性FLT3突变急性髓系白血病患者,接受吉瑞替尼单药或联合治疗,复合完全缓解率为48.7%(n=55)。仅接受过7+3方案和米哚妥林(联合或不联合巩固治疗)的患者复合完全缓解率为58%,中位生存7.8个月。获得完全缓解尤其cMRD阴性者生存最长;携带NRAS、KRAS或PTPN11突变者复合完全缓解率更低(35% vs 60.5%),中位总生存更短(4.9个月 vs 7.8个月)(HR 2.4;P<.01)。
要点
- 复发/难治性FLT3突变急性髓系白血病接受吉瑞替尼的复合完全缓解率为48.7%(n=55)。
- 仅接受过7+3和米哚妥林(联合或不联合巩固)者复合完全缓解率为58%,中位生存7.8个月。
核心结论
- 吉瑞替尼在既往接受过FLT3抑制剂治疗的复发/难治性FLT3突变急性髓系白血病中显示出临床活性,复合完全缓解率为48.7%(n=55)。
- 获得完全缓解尤其cMRD阴性者生存最长,该关联在剔除干细胞移植时点后仍显著。
研究设计与样本
- 回顾性分析,使用来自11家美国中心的数据。
- 共纳入113例接受吉瑞替尼单药或联合治疗复发/难治性FLT3突变急性髓系白血病的患者。
主要发现
- 复合完全缓解率(CRc,定义为CR+CRi+血小板未完全恢复的CR[CRp])为48.7%(n=55)。
- 仅接受过7+3方案和米哚妥林(联合或不联合巩固治疗)的患者接受吉瑞替尼后复合完全缓解率为58%,中位生存7.8个月。
- 获得完全缓解尤其cMRD阴性者的生存最长,该关联在剔除干细胞移植时点后仍显著。
关键数值与推荐
- 复合完全缓解率定义为CR+CRi+CRp。
- 吉瑞替尼已获批用于复发/难治性FLT3突变急性髓系白血病。
- 吉瑞替尼3期ADMIRAL研究在米哚妥林作为标准强化诱导和巩固方案组成部分或移植后FLT3抑制剂维持治疗广泛采用之前开展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3-mutation (FLT3mut+ ). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either midostaurin as a component of standard intensive induction and consolidation or posttransplant FLT3 inhibitor maintenance. We performed a retrospective analysis using data from 11 US centers and where we identified 113 patients who received gilteritinib alone or as combination therapy for the treatment of R/R FLT3mut+ AML. The composite complete remission (CR) rate (CRc, defined as CR + CRi + CR with incomplete platelet recovery [CRp]) was 48.7% (n = 55). The CRc rate after treatment with gilteritinib in patients who were treated with only prior 7+3 and midostaurin with or without consolidation was 58% with a median survival of 7.8 months. Survival was longest in patients who obtained a CR, particularly a cMRD (clinical minimal or measurable residual disease) negative response; this remained significant after censoring at the time of stem cell transplant. The mitogen-activated protein kinase pathway activating mutations that are known for gilteritinib resistance (NRAS, KRAS, and PTPN11) had lower CRc (35% vs. 60.5%) and lower median overall survival than patients' whose leukemia did not express these mutations (4.9 months vs. 7.8 months) (HR 2.4; 95% CI 1. 5.4) p value <.01.
引用
- Numan Y, Abdel Rahman Z, Grenet J, et al. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022. PMID: 34981560. doi:10.1002/ajh.26447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。